ReproNovo, a biopharmaceutical company developing therapies for reproductive medicine and women’s health, has raised $65 million in Series A financing to advance its Phase 2 clinical programs.
The funding round was led by Jeito Capital, co-led by AXA IM Alts and founding investor M Ventures, with additional support from Ysios Capital and ALSA Ventures. The company plans to use the proceeds to advance its pipeline of treatments targeting male and female infertility as well as uterine health conditions.
Founded in 2021, ReproNovo has rapidly built a pipeline with two Phase 2 clinical-stage assets across three disease areas. The company’s lead candidate, RPN-001 (leflutrozole), is an orally administered therapy being developed for infertility in men with low serum testosterone, a condition that is becoming increasingly prevalent even among younger men.
“We are focused on innovative therapeutic solutions for male and female infertility, as well as pioneering management options for conditions like adenomyosis,” said Jean Marie Duvall, Co-Founder and Chief Executive Officer of ReproNovo. “Our aim is to address critical gaps in the landscape of infertility and women’s health worldwide.”
The company’s second compound, RPN-002 (nolasiban), is described as a first-in-disease and first-in-class therapy to manage adenomyosis, a condition involving overgrowth of endometrial tissue into the uterus that can cause severe menstrual bleeding and pain. According to the company, recent imaging studies have identified features of adenomyosis in nearly one in four women undergoing gynecological evaluation. RPN-002 will also be explored for improving success rates in assisted reproductive technologies.
“As around one in six people worldwide will face infertility issues, we are proud to support ReproNovo, whose commitment to advancing novel therapies in reproductive health aligns well with our focus on accelerating cutting-edge technologies,” said Ksenija Pavletic, Partner and Chief Commercial Officer at Jeito Capital.
The company has established operations across Europe, with headquarters in Lausanne, Switzerland, its primary development team in Copenhagen, Denmark, and an additional development site in Barcelona, Spain.
